Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 77 Total
ABOS - Acumen Pharmaceuticals Inc - Stock Price Chart
TickerABOS [NASD]
CompanyAcumen Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap213.88MEPS (ttm)-1.08
P/E-EPS this Y-8.54%
Forward P/E-EPS next Y-19.34%
PEG-EPS past 5Y-54.03%
P/S-EPS next 5Y22.89%
P/B0.77EPS Q/Q9.53%
Dividend-Sales Q/Q-
Insider Own26.14%Inst Own55.52%
Insider Trans-0.22%Inst Trans4.20%
Short Float2.09%EarningsMay 14/b
Analyst Recom1.00Target Price13.50
Avg Volume317.55K52W Range1.81 - 11.31
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OConnell Daniel JosephPresident and CEOJan 19 '24Sale3.4715,20052,753502,485Jan 19 07:07 PM
Meisner Derek MChief Legal Officer & Corp SecJan 19 '24Sale3.488,93331,048108,867Jan 19 07:06 PM
Zuga MattCFO & Chief Business OfficerJan 18 '24Sale3.714,24215,717211,445Jan 19 07:05 PM
Siemers EricChief Medical OfficerJan 18 '24Sale3.713,12411,604117,576Jan 19 07:05 PM
Barton RussellChief Operating OfficerJan 18 '24Sale3.732,83310,55596,867Jan 19 07:04 PM
ABSI - Absci Corp - Stock Price Chart
TickerABSI [NASD]
CompanyAbsci Corp
CountryUSA
IndustryBiotechnology
Market Cap557.87MEPS (ttm)-1.20
P/E-EPS this Y29.72%
Forward P/E-EPS next Y9.29%
PEG-EPS past 5Y-46.78%
P/S97.53EPS next 5Y23.30%
P/B2.61EPS Q/Q-19.28%
Dividend-Sales Q/Q-78.29%
Insider Own21.16%Inst Own34.81%
Insider Trans0.94%Inst Trans3.16%
Short Float9.06%EarningsMay 14/b
Analyst Recom1.33Target Price8.60
Avg Volume1.39M52W Range1.11 - 6.72
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLCDirectorMar 01 '24Buy4.50222,222999,9998,253,316Mar 05 09:30 PM
ACRV - Acrivon Therapeutics Inc - Stock Price Chart
TickerACRV [NASD, RUT]
CompanyAcrivon Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap263.87MEPS (ttm)-2.73
P/E-EPS this Y-1.79%
Forward P/E-EPS next Y1.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.59EPS Q/Q-101.64%
Dividend-Sales Q/Q-
Insider Own32.95%Inst Own62.80%
Insider Trans30.08%Inst Trans-
Short Float5.24%EarningsMay 14/b
Analyst Recom1.20Target Price21.22
Avg Volume791.15K52W Range3.19 - 14.30
Today 08:00AM Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire)
Apr-16-24 08:01PM Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire)
Apr-10-24 08:00AM Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM
Chione Ltd10% OwnerJun 26 '23Sale12.93162073,848,632Jun 28 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16 '23Option Exercise3.639,50034,48529,530Jun 20 05:21 PM
Chione Ltd10% OwnerJun 15 '23Sale12.142,05624,9603,848,648Jun 20 05:15 PM
Chione Ltd10% OwnerJun 14 '23Sale12.1389310,8323,850,704Jun 14 06:33 PM
ALIM - Alimera Sciences Inc. - Stock Price Chart
TickerALIM [NASD]
CompanyAlimera Sciences Inc.
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap171.77MEPS (ttm)-2.16
P/E-EPS this Y98.73%
Forward P/E16.00EPS next Y2150.00%
PEG-EPS past 5Y21.42%
P/S2.13EPS next 5Y-
P/B3.72EPS Q/Q87.13%
Dividend-Sales Q/Q87.51%
Insider Own9.92%Inst Own93.09%
Insider Trans0.00%Inst Trans0.45%
Short Float0.26%EarningsMay 14/b
Analyst Recom1.00Target Price8.00
Avg Volume75.75K52W Range1.64 - 4.38
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caligan Partners LP10% OwnerSep 14 '23Buy3.39579,0001,962,81016,835,154Sep 15 04:05 PM
Caligan Partners LP10% OwnerSep 14 '23Sale3.39579,0001,962,81016,256,154Sep 15 04:05 PM
Morgan AdamDirectorMay 17 '23Buy1.701,401,9012,383,2321,659,654May 19 05:17 PM
ALUR - Allurion Technologies Inc - Stock Price Chart
TickerALUR [NYSE]
CompanyAllurion Technologies Inc
CountryUSA
IndustryMedical Devices
Market Cap88.65MEPS (ttm)-4.34
P/E-EPS this Y62.58%
Forward P/E-EPS next Y44.87%
PEG-EPS past 5Y-
P/S2.25EPS next 5Y-
P/B-EPS Q/Q-3253.12%
Dividend-Sales Q/Q-
Insider Own24.13%Inst Own19.07%
Insider Trans0.00%Inst Trans-8.35%
Short Float1.45%EarningsMay 14/b
Analyst Recom1.00Target Price5.00
Avg Volume1.04M52W Range1.56 - 10.94
Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chardon BenoitChief Commercial OfficerDec 12 '23Option Exercise1.19165,539197,562199,183Dec 14 07:17 PM
APRE - Aprea Therapeutics Inc - Stock Price Chart
TickerAPRE [NASD]
CompanyAprea Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap32.04MEPS (ttm)-4.00
P/E-EPS this Y34.26%
Forward P/E-EPS next Y41.21%
PEG-EPS past 5Y23.41%
P/S55.24EPS next 5Y-
P/B1.30EPS Q/Q94.99%
Dividend-Sales Q/Q-
Insider Own11.91%Inst Own18.84%
Insider Trans2.66%Inst Trans-45.51%
Short Float1.90%EarningsMay 14/b
Analyst Recom1.00Target Price15.67
Avg Volume30.73K52W Range2.78 - 8.85
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seizinger Bernd R.DirectorMar 13 '24Buy7.296,86050,00933,685Mar 14 08:53 PM
HENNEMAN JOHN B IIIDirectorMar 13 '24Buy7.296,86050,0098,139Mar 14 08:52 PM
Gilad OrenPresident, CEOMar 13 '24Buy7.292,00014,580324,770Mar 14 08:51 PM
Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrMar 13 '24Buy7.291,0107,36315,503Mar 14 08:54 PM
Seizinger Bernd R.DirectorJun 07 '23Buy3.686,02922,19226,325Jun 08 04:34 PM
ARKR - Ark Restaurants Corp. - Stock Price Chart
TickerARKR [NASD]
CompanyArk Restaurants Corp.
CountryUSA
IndustryRestaurants
Market Cap48.42MEPS (ttm)-1.76
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.26EPS next 5Y-
P/B0.94EPS Q/Q-20.22%
Dividend5.58%Sales Q/Q0.09%
Insider Own50.45%Inst Own17.20%
Insider Trans0.00%Inst Trans7.03%
Short Float0.91%EarningsMay 14/b
Analyst Recom-Target Price-
Avg Volume2.38K52W Range10.27 - 18.75
May-13-24 08:53PM ARKR Stock Earnings: Ark Restaurants Reported Results for Q2 2024 (InvestorPlace)
04:28PM Ark Restaurants: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:20PM Ark Restaurants Announces Financial Results for the Second Quarter of 2024 (Business Wire)
May-09-24 04:05PM Ark Restaurants Announces Conference Call (Business Wire)
May-07-24 04:20PM Ark Restaurants Announces Declaration of Dividend (Business Wire)
Feb-16-24 08:12AM Ark Restaurants Corp. (NASDAQ:ARKR) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-14-24 12:04AM Q1 2024 Ark Restaurants Corp Earnings Call (Thomson Reuters StreetEvents) +5.36%
Feb-12-24 04:25PM Ark Restaurants: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:20PM Ark Restaurants Announces Financial Results for the First Quarter of 2024 (Business Wire)
Feb-07-24 04:05PM Ark Restaurants Announces Conference Call (Business Wire)
Ark Restaurants Corp. engages in the operation of restaurants and bars, fast food concepts, and catering operations. It operates in New York City, Florida, Washington, D.C, Las Vegas, NV, and the gulf coast of Alabama. The company was founded on January 4, 1983 and is headquartered in New York, NY.
AUMN - Golden Minerals Co - Stock Price Chart
TickerAUMN [AMEX]
CompanyGolden Minerals Co
CountryUSA
IndustryOther Precious Metals & Mining
Market Cap7.32MEPS (ttm)-1.16
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-120.57%
P/S0.61EPS next 5Y-
P/B1.38EPS Q/Q84.62%
Dividend-Sales Q/Q-93.46%
Insider Own13.40%Inst Own2.76%
Insider Trans0.00%Inst Trans-9.88%
Short Float13.07%EarningsMay 14/b
Analyst Recom1.00Target Price3.10
Avg Volume444.29K52W Range0.26 - 4.95
Golden Minerals Co. engages in the exploration of gold and silver resource properties. It focuses on a portfolio of precious metals projects which include Velardena Properties and the Rodeo gold project in Durango State, Mexico, the El Quevar silver project in Salta province of Argentina, the Yoquivo gold-silver district-scale project in Chihuahua, Mexico, the Sand Canyon gold-silver project in northwestern Nevada, and additional traditional silver-producing projects in Mexico. The company was founded in 1996 and is headquartered in Golden, CO.
AUTL - Autolus Therapeutics plc ADR - Stock Price Chart
TickerAUTL [NASD]
CompanyAutolus Therapeutics plc ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap698.05MEPS (ttm)-1.20
P/E-EPS this Y42.59%
Forward P/E-EPS next Y17.38%
PEG-EPS past 5Y3.32%
P/S410.62EPS next 5Y-
P/B6.26EPS Q/Q-92.78%
Dividend-Sales Q/Q-100.00%
Insider Own9.38%Inst Own63.69%
Insider Trans0.00%Inst Trans-1.84%
Short Float2.23%EarningsMay 14/b
Analyst Recom1.36Target Price10.69
Avg Volume1.60M52W Range2.01 - 7.45
Today 10:00AM Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress (GlobeNewswire)
May-13-24 11:15AM Autolus Therapeutics Announces Delay of Q1 Earnings Release (MT Newswires)
07:00AM Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call (GlobeNewswire)
Apr-24-24 10:00AM Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO (GlobeNewswire) -6.03%
Apr-23-24 07:00AM Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-02-24 07:00AM Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (GlobeNewswire)
Apr-01-24 07:00AM Autolus Therapeutics Announces Changes to its Board of Directors (GlobeNewswire) -10.97%
Mar-21-24 01:43AM Q4 2023 BioNTech SE Earnings Call (Thomson Reuters StreetEvents)
Mar-17-24 09:19AM Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 05:53AM Q4 2023 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
BABA - Alibaba Group Holding Ltd ADR - Stock Price Chart
TickerBABA [NYSE]
CompanyAlibaba Group Holding Ltd ADR
CountryChina
IndustryInternet Retail
Market Cap189.36BEPS (ttm)5.49
P/E14.40EPS this Y-5.03%
Forward P/E8.50EPS next Y13.92%
PEG1.42EPS past 5Y1.29%
P/S1.45EPS next 5Y10.11%
P/B1.39EPS Q/Q-68.77%
Dividend1.05%Sales Q/Q3.45%
Insider Own0.22%Inst Own14.15%
Insider Trans0.00%Inst Trans-10.92%
Short Float1.84%EarningsMay 14/b
Analyst Recom1.52Target Price102.97
Avg Volume14.58M52W Range66.63 - 102.50
Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.
12345678